ADMA Biologics Inc近日回应一份做空报告,明确指出该报告对旗下产品Asceniv在静脉注射免疫球蛋白(IVIG)市场的实际效用及竞争地位存在严重曲解和混淆。公司强调,报告中的指控未能准确反映Asceniv的临床价值与市场定位。
ADMA Biologics Inc近日回应一份做空报告,明确指出该报告对旗下产品Asceniv在静脉注射免疫球蛋白(IVIG)市场的实际效用及竞争地位存在严重曲解和混淆。公司强调,报告中的指控未能准确反映Asceniv的临床价值与市场定位。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.